Metastasis is the leading cause of death in many cancers. Metastases are particularly harmful when they affect vital organs such as the brain or liver, severely compromising the patient’s quality of life and leading to death. The difficulties of studying metastases in animal models (time, cost, ethical issues) have meant Read more…
In recent years, 3D cell culture has emerged as a promising approach to studying the immune system and its interactions with cancer cells. Indeed, 3D cell culture mimics better the natural architecture of tissues and provides a more physiologically relevant models for drug discovery. One of the major advantages of Read more…
The Building Biology in 3D symposium of the Society for Laboratory Automation and Screening (SLAS) took place in Cambridge, United Kingdom, on March 20th and 21th 2023. This congress was the opportunity to discover the dynamic scientific environment of Cambridge. Because this event was focusing on 3D cell culture, most Read more…
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
… And it is right ! “Biomimesys technology can bring several advantages in immuno-oncology by providing a more physiologically relevant 3D cell culture model for research. This technology uses a bioinspired extracellular matrix to create a three-dimensional environment that more closely resembles the natural cellular environment. In immuno-oncology, 2D cell Read more…
Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 21th 2023. Title: 3D cell culture taking into account the extracellular matrix for phenotypic screening in the frame of Parkinson’s disease V. De Conto 1*, Cheung V.1, Alejandra Mogrovejo – Valdivia1, Maubon N.1, Vandenhaute E.1, Read more…
Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 20th 2023. Title: 3D cell culture taking into account the extracellular matrix for bridging the gap between in vitro & in vivo: focus on cancer models V. De Conto 1 *, M. Fernandes2, J. Cicero, Read more…
The event “Research and Innovation 2023 – Accelerating future DD” of The European Laboratory Research and Innovation Group (ELRIG) took place in Cambridge on March 29th and 30th 2023. Our project leader Dr. Veronique De Conto attended this event with our academic partner Dr.Marie Fernandes (CNRS, Oncolille, Canther Lab), who Read more…
HCS Pharma is very pleased to participate to “Building Biology in 3D” symposium of the Society for Laboratory Automation and Screening (SLAS), in Cambridge, United Kingdom 20-21 April 2023. Veronique De Conto, our project leader in in vitro pharmacology will present two digital posters about the use of BIOMIMESYS® hydroscaffold, Read more…
It is with great pleasure that we announce the reinforcement of our collaboration about lung cancer between HCS Pharma and TARGET team of the OncoLille Institute (Team “Efficacy and resistance to anti-tumor targeted therapies”, CANTHER UMR9020, Lille, France). Initially supported by Région Hauts-de-France, this project has been initiated in spring Read more…
Why is testing important? One million cases of colon cancer are diagnosed each year around the world. Colorectal cancer develops slowly. The tumor, called polyp, appears on the inner wall of the colon and rectum. The evolution of a polyp into cancer can last about ten years. The test can Read more…
We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet us and to present you our disruptive technology BIOMIMESYS®. Read more…
The Brain Week is an international event organized simultaneously in about 100 countries and more than 120 cities in France. Its aim is to raise public awareness of the importance of brain research. It is an opportunity for many researchers to meet the public and share with them the advances Read more…
2.2 million cases of breast cancer were identified in 2020 by the WHO. This cancer is the first cause of cancer in women. It develops in the glandular lobes or milk ducts. Five subtypes of breast cancer have been defined but their origin is not yet determined. The heterogeneity of Read more…
After obtaining this Master’s degree in Biology and Health Science at Lille University in 2022, Nathan Laneret has just begun a PhD thesis under the supervision of Pr. RA Toillon and Dr. Nathalie Maubon thanks to ANRT fundings (CIFRE). Through this collaboration between the Cellular Plasticity and Cancer team from Canther Lab Read more…
It is a pleasure to announce that HCS Pharma has a new collaborative project dealing with Inflammasome et ion channels Team of OncoLille (PHYCELL Lab, INSERM U1003) in the frame of colon cancer, thanks to France Relance plan and Region Hauts-de-France. This project has started in October 2022 for 2 Read more…
We are pleased to welcome Paul Couvreur as a commercial apprentice on board of HCS Pharma. Graduated in international trade and now in an international business Master, Paul decided to get on board of HCS Pharma company as work-study student. His promise? Bring a commercial support in the pharmacology service Read more…
The congress of European Society of Toxicology In Vitro (ESTIV) took place from 21st to 25th November 2022. This congress is focus on the alternative methods to animal testing, including both in silico and in vitro modeling. After a nice opening ceremony with a flamenco show, the scientific program begun Read more…
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
In October the expansion works started in HCS Pharma. The objective is to double the lab and office surface in the same building as our current premises, in the aim to expand BIOMIMESYS® production line to meet the growing demand while guaranteeing the quality of the products. These works will Read more…
